Neuroendocrine differentiation and clinical behaviour in non-small cell lung tumours. by Sundaresan, V. et al.
Br. J. Cancer (1991), 64, 333 338 t. Macmillan Press Ltd.,
Neuroendocrine differentiation and clinical behaviour in non-small cell
lung tumours
V. Sundaresan'2, J.G. Reeve', S. Stenning', S. Stewart2 & N.M. Bleehen'
'University Department and MRC Clinical Oncology and Radiotherapeutics Unit, Hills Road, Cambridge; 2Department of
Histopathology, Addenbrooke's Hospital, Hills Road, Cambridge, UK.
Summary The present study examines the relationship between neuroendocrine (NE) differentiation and the
clinical behaviour of non-small cell lung cancer (NSCLC). Retrospective (n = 315) and prospective (n = 44)
cohorts of non-small cell tumours were obtained from surgically treated cases of lung cancer, comprising 218
squamous cell carcinomas, 65 adenocarcinomas, 51 adenosquamous carcinomas, and 25 large cell undifferent-
iated carcinomas. Paraffin wax embedded and fresh frozen tissue sections were stained for the NE markers
neurone specific enolase, creatine kinase-BB, bombesin, neurotensin, chromogranin A, synaptophysin and
UJ-13A. The expression of two or more markers was observed in 30% of cases, and was taken to identify
NE-NSCLC. A statistically significant correlation between nodal status and NE differentiation (P = 0.05), and
disease stage and NE differentiation (P = 0.04) was observed. However, there was no correlation between NE
differentiation and survival. These findings suggest that NE-NSCLC, analogous to SCLC is more highly
metastatic than non-NE-NSCLC.
A number of studies have demonstrated the presence of
neuroendocrine (NE) markers in non-small cell lung cancer
(NSCLC). These include L-dopa decarboxylase (Baylin et al.,
1980; Berger et al., 1981; Gazdar et al., 1988a), peptide
hormones including calcitonin (Berger et al., 1981) and gas-
trin releasing peptide (Yamaguchi et al., 1985) and neurone
specific enolase (NSE) (Bergh et al., 1985; Said et al., 1985;
Rode et al., 1985; Dhillon et al., 1985; Linnoila et al., 1988b;
Graziano et al., 1989). Although elevated levels of neuro-
endocrine (NE) markers have been detected in NSCLC
tumours, the expression of more than one NE marker,
though common in small cell lung cancer (SCLC) occurs
much less frequently in NSCLC (Berger et al., 1981). Recent
immunohistochemical studies have shown the presence of
multiple NE markers in 10-20% of NSCLC (Gazdar, 1986;
Linnoila et al., 1988b; Berendsen et al., 1989). The occurrence
of NE differentiation in NSCLC tumours is significant not
only because it suggests that the major forms of lung cancer
represent a continuum of differentiation within a common
cell lineage, but also because the response of neuroendocrine
NSCLC (NE-NSCLC) to chemotherapy has been shown to
be similar to that of SCLC. In vitro drug sensitivity testing of
SCLC, NSCLC and NE-NSCLC cell lines has shown that
SCLC and NE-NSCLC cell lines are more responsive to
cytotoxic drug treatment than non-NE-NSCLC (Gazdar,
1986). Similarly, several studies have shown that patients
with NE-NSCLC show increased response to chemotherapy
compared to patients with non-NE-NSCLC tumours (Mul-
shine et al., 1987; Gazdar et al., 1988b; Linnoila et al., 1988a;
Berendsen et al., 1989; Graziano et al., 1989).
These findings on drug response show that the clinical
behaviour of NE-NSCLC tumours is similar to that of
SCLC. A second clinical characteristic of SCLC is the aggres-
sive nature of the disease and its propensity for early and
extensive metastatic spread. To further evaluate the clinical
significance of NE differentiation in NSCLC, the present
study examines the relationship between the expression of
NE markers, metastatic spread and survival in surgically
operable NSCLC patients.
A panel of neuroendocrine markers has been used to
screen for NE properties in a prospective (n = 44) and retro-
spective (n = 315) collections of NSCLC tumour samples.
Markers selected for study include: NSE, an isoenzyme of the
glycolytic enzyme enolase which has been identified as a
marker for SCLC and other NE tumours (Schmechl et al.,
1978; Marangos et al., 1982); creatine kinase BB (CK-BB)
found in large amounts in the brain, gastro-intestinal tract
and SCLC (Gazdar et al., 1981); chromogranin-A, a protein
which stabilises the intragranular matrix of neurosecretory/
dense core granules (DCG) (Bishop et al., 1988); protein gene
product 9.5 (PGP 9.5), a ubiquinated protein (Wilkinson et
al., 1989) reported to be present in nerves, neuroendocrine
tissues and associated benign and malignant tumours (Rode
et al., 1985); bombesin-like peptides and neurotensin, hor-
mones often elaborated by SCLC and other neuroendocrine
tumours (Moody et al., 1981; Hamid et al., 1987); synapto-
physin, a membrane protein isolated from presynaptic vesi-
cles of bovine neurones, and reported to be present in the
normal neural and neuroendocrine tissues and tumours asso-
ciated with them (Gould et al., 1986); and finally we have
examined the expression of the cell surface protein NCAM
(neural cell adhesion molecule), which is recognised by the
monoclonal antibody UJ-13A (Patel et al., 1989; Allan et al.,
1983).
Materials and methods
Retrospective cases
Three hundred and fifteen cases of NSCLC presenting
between 1978-1989 and treated surgically by thoracotomy
and subsequent pneumonectomy, lobectomy or segmentec-
tomy, were obtained from Papworth Hospital, Papworth,
Cambridge, UK. Selection of cases was determined by the
availability ofwell-fixed paraffin wax embedded material with
sufficient tumour material for multiple serial sections. The
pathological material and reports were reviewed and tumours
were classified according to the revised WHO classification of
lung carcinoma (WHO, 1981). Tumours were examined by
two pathologists and where there was dispute, cases were
re-examined and consensus reached.
All tumours showing evidence of bronchio-alveolar type of
carcinoma were excluded from the study, as were metastatic
adenocarcinomas. Carcinoid tumours (n = 17) and SCLC
(n = 19) were included in the study as control tissue for the
assessment of antibody reactivity.
One tumour block was selected per case. Sections were
stained with haematoxylin and eosin to confirm the original
histological diagnosis. Where there was morphological evi-
dence of glandular differentiation, alcian blue PAS stain with
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diasatase pre-digestion was carried out to confirm the pre-
sence of mucin.
Retrospective cases were staged according to the TNM
classification (Hermanek et al., 1987), using information
derived from the clinical notes and pathological reports. The
TNM category and stage of the tumour were determined by
the criteria as laid down by the American Thoracic Society.
The volume of the primary tumour was estimated from the
maximum diameter of the lesion after fixation of lung in
formal saline. The T category was determined by tumour
size: TI lesions being less than 3 cm in diameter; T2 lesions
being larger than 3 cm diameter, and T3 cases being locally
invasive tumours infiltrating the parietal pleura and the con-
tiguous chest wall or intra-thoracic viscera. The nodal status,
NO, NI and N2 were determined by the absence of hilar
nodes, positive hilar lymphoadenopathy, and mediastinal
lymph node involvement respectively. Tumour stages I, II, III
were derived from various combinations of the T, N and M
status (Hermanek et al., 1987).
Clinicalfollow up
Survival data were available for 309 of the 315 patients and
were obtained from the Cancer Registry Office, Cambridge,
the clinical case notes at Papworth Hospital, and for patients
outside the East Anglia Health Authority, from general prac-
titioners.
Prospective cases
Fresh tumour material was obtained from lung cancer cases
treated surgically between 1987 and 1989 at Papworth Hos-
pital, Cambridge, UK and Charing Cross Hospital, London,
UK (n = 47). Fresh tumour samples were subdivided, frozen
in liquid nitrogen and stored at - 70°C, or, also fixed in
acetic alcohol for immunocytochemistry. Tumour material
(n = 35) was also fixed in glutaraldehyde and subsequently
processed for electron microscopy.
Normal tissues
A range of normal tissues were included in the study to
assess antibody specificity for neuroendocrine tissues. These
included pancreas, small and large bowel, testis, thyroid,
pituitary, adrenal gland, adult and foetal lung, bronchus,
kidney, muscle, brain, spinal cord, spleen and lymph node
which were obtained from surgically resected specimens and
fresh post-mortem cases. These were fixed in neutral buffered
formal saline, processed and embedded in paraffin wax.
Antibodies
The majority of antibodies were obtained from commercial
sources as detailed in Table I. UJ-13A was generously dona-
ted by Dr John Kemshed (ICRF Oncology Laboratory, Insti-
tute of Child Health, London, UK) and was used only on
frozen material. Commercially available antibodies were
selected on the basis of high immunogen purity thus limiting
the potential for cross reactivity (see Table I). Each of the
primary antibodies was specifically titrated for the study
using control tissue. Dilutions were considered optimal when
each of the antibodies specifically stained SCLC, carcinoid
tumours, pulmonary neuroendocrine cells, and/or, pancreatic
islets, or nerves within the control tissue sections. In addition
to normal tissue reactivity, antibody specificity was confirmed
for each antibody by blocking studies with the immunogen
concerned, except for antibodies to synaptophysin, PGP 9.5,
UJ-13A and chromogranin-A.
The anti-synaptophysin antibody, although commercially
marketed as suitable for formalin fixed paraffin wax embed-
ded tissues, showed much background staining. This con-
trasted with acetyl alcohol fixed paraffin wax embedded
material, where there was good delineation of NE tissues.
Hence this antibody was restricted for use on acetic alcohol
fixed material.
The anti-PGP 9.5 antibody also stained renal tubular epi-
thelium and other non-neuroendocrine tissues. Other studies
have also detected PGP 9.5 in a variety of non-NE tissues
(Wilson et al., 1988) and hence this marker was excluded
from the rest of this study.
Immunohistochemistry
A brief outline of the method for immunostaining is as
follows: 5 gsm sections were dewaxed in xylene, rehydrated in
graded alcohols to distilled water. Endogenous peroxidase
was blocked by pretreatment of all sections in 10% hydrogen
peroxide for 10min. Sections were treated sequentially with
(i) bovine serum albumin for 10min; (ii) primary antisera
appropriately diluted (see Table I) in Tris buffered saline
(TBS), at 4°C overnight for 17 h; (iii) three 10 min washes in
TBS; (iv) biotinylated swine anti-rabbit serum diluted (1/200)
for 30 min; (v) three 10 min washes in TBS; (vi)-avidin-biotin
peroxidase conjugate complex (Dakopatts, UK) for 30min
followed by washing in TBS for a further 10 min. The peroxi-
dase colour was visualised by incubation in diamino benzi-
dine for 5 min, followed by washing in TBS for 10 min.
Slides were lightly counterstained with Harris's haemotoxy-
lin. In addition to the aforementioned specificity controls,
substitution of each primary antiserum with normal rabbit
serum or TBS was carried out for every tumour examined.
The staining of tumours was assessed using light micro-
scopy, and positivity was scored on a scale of + 1 to + 3,
where + 1 was weak but greater than background staining
and + 3 intense staining. Tumours were recorded as positive
for individual markers when positive staining was identified
in at least 5% of the section. The staining of keratin pearls,
seen occasionally in well differentiated squamous cell car-
cinoma, was considered non-specific.
Table I Details ofantibodies used and working dilutions
Working
Antibody to Immunogen Host Supplier dilution
NSE Rat brain NSE, Rabbit Cambridge Research 1:500
purified protein Biochemicals, UK
PGP 9.5 (PGP) Human brain extract Rabbit Ultraclone Ltd, 1:500
Cambridge, UK
Chromagranin-A (CGA) Phaeochromocytoma Rabbit Hybritech Europe, UK 1:40
solid tissue extract
Neurotensin (NT) Synthetic bovine Rabbit Amersham International PLC, 1:500
neurotensin UK
Synaptophysin (SYN) Presynaptic vesicle Rabbit Dako Ltd, UK 1:10
from bovine brain
Bombesin-like peptides Synthetic amphibian Rabbit Amersham International PLC, 1:600
(BLP) bombesin UK
Creatine Kinase BB Highly pure human Rabbit Biogenesis Ltd, UK 1:400
(CKBB) creatine kinase BB
UJ-13A Human foetal brain Mouse J. Kemshed, ICRF, 1:10
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Table II Reactivity of antibodies with selected normal tissues
NSE PGP CGA CKBB BLP NT SYN UJ-13A
Tissues
Bronchial NE cells
Foetal ++ +++ +++ +++ ++ +++ NS ND
Adult ++ + + + + NS NS NS NS ND
Adrenal
Cortex NS NS NS NS NS NS NS NS
Medulla +++ +++ ++ + NS ++ + ++
Pancreas
Acini NS NS NS NS NS NS NS ND
Islets +++ +++ +++ + + ++ ++ ND
Small bowel
NE cells + + + + + NS NS NS + ND
Glands NS NS NS NS NS NS NS ND
Nerves + + + +++ NS NS NS NS NS ND
Stomach
NEcells ++ +++ +++ +++ ++ ++ + ND
Glands NS NS NS NS NS NS NS ND
Thyroid
C-cells +++ +++ +++ ++ +++ ++ NS ND
Follicles NS NS NS NS NS NS NS ND
Kidney
Tubules NS + + + NS NS NS NS NS NS
NS - No staining; + weak; + + moderate; + + + intense staining. ND - not done.
Statistical analysis
Correlation between categorical variables was assessed using
chi-squared tests. Survival curves were compared using the
log rank test (Peto et al., 1977). Multivariate analysis using
Cox's proportional hazards regression model (Tibshirani,
1982) and a forward stepwise variable selection procedure
was employed to identify factors of independent prognostic
importance. The primary endpoint used was death from lung
cancer, although analysis according to all-cause mortality
was also carried out.
Results
Antibody reactivity with normal tissues
The pattern of antibody reactivity with normal tissues is
summarised in Table II. It can be seen that with the excep-
tion of anti PGP 9.5 antiserum, the antibodies selected for
the study are specific for neuroendocrine tissues.
Table III Immunohistochemical results of retrospective series
% oftumours showing positivityfor
Histology/ Number NSE CGA CKBB BLP NT
Carcinoid 17 83 35 41 30 53
SCLC 9 78 0 67 67 45
SQC 191 40 1 13 18 25
Ad-SQ 45 46 0 22 18 43
Adeno 58 58 0 33 20 20
LCU 21 60 0 33 10 33
Total 315 44 1 19 9 26
NSCLC
'SQC = Squamous cell carcinoma, Ad-SQ = Mixed adeno-squamous
carcinoma, Adeno = Adenocarcinoma, LCU = Large cell undifferent-
iated carcinoma.
Expression ofmarkers in tumoursfrom retrospective cases
Table III summarises the immunohistochemical results. It can
be seen that the vast majority of SCLC and carcinoid
tumours staining positively for NSE, and that an average of
44% of NSCLC also showed positivity for this marker.
Chromogranin A immunostaining was present in one third of
carcinoid tumours and in none of the SCLC tumours. Less
than 1% of the NSCLC tumours were positive for this
marker. CK-BB was detected in 41% and 67% of carcinoid
tumours and SCLC tumours respectively. In the NSCLC
group CK-BB immunoreactivity was detected on average in
19% of NSCLC tumours. Bombesin like immunoreactivity
was present in 30% of carcinoid tumours and in 67% of
SCLC. In comparison, 9% of NSCLC were positive for this
marker. Neurotensin was detected in 53% of carcinoid
tumours, 45% of SCLC and in an average of 26% of
NSCLC tumours.
Table IV shows the frequency of tumours expressing
nought to four markers. No statistically significant correla-
tion existed between marker positivity and NSCLC histo-
logical subtype. It can be seen that 95% of the carcinoid
Table IV Percentage of tumours showing 0, 1, 2, 3 and 4 markers
retrospective series
No. ofmarkers
0 1 2 3 4
Histology No. % positive
Carcinoid 17 6 - 65 18 12
SCLC 9 11 - 44 11 33
SQC 191 50 24 17 6 3
Ad-SQ 45 31 31 22 9 7
Adeno 58 28 31 20 19 2
LCU 21 33 24 19 19 5
Total NSCLC 315 42 28 18 9 3
Table V Immunohistochemical results of prospective series
% of tumours showing positivityfor
Histology Number NSE CGA CKBB BLP NT Syn UJ-13A
Carcinoid 3 100 66 66 0 33 66 33
SQC 27 50 7 14 4 10 19 14
Ad-SQ 6 100 16 16 16 0 66 16
Adeno 7 42 0 0 14 14 0 14
LCU 4 50 0 0 0 0 75 50
Total NSCLC 44 57 7 11 7 10 23 20336 V. SUNDARESAN et al.
tumours and 88% of the SCLC cases showed positivity for
two or more markers. Thirty per cent of the NSCLC cases
also were positive for two or more of the markers and these
were taken to represent NE-NSCLC tumours.
Expression ofmarkers in tumoursfrom prospective cases
Table V summarises the immunohistochemical results for the
prospective cohort of tumours. No SCLCL cases were treat-
ed surgically during the collection time of histological
material for this study. Table VI summarises the frequency of
neuroendocrine marker positivity according to histologic sub-
type. As in the retrospective group, it can be seen that 30%
of NSCLC tumours showed positivity for two or more
markers.
Ultrastructuralfeatures and immunohistochemical results
Of the 34 cases of NSCLC with material for electron micro-
scopy, 47% showed evidence of DCGs. The number of
DCGs varied from case to case with variation in size of
granules from 100 to 250 nm. The presence of DCGs cor-
related significantly with the presence of two or more
markers in NE differentiation (X2 = 5.46, on 1 d.f., P = 0.01)
DCGs being detected in nine out of ten NSCLC tumours
showing two or more markers (Table VII). All three NSCLC
cases which exhibited chromogranin-A positivity in the pro-
spective group showed modest numbers of DCGs. The
remaining cases with DCGs did not show immunohisto-
chemical evidence of chromogranin-A positivity.
Clinical behaviour ofNE-NSCLC
Clinical data for patients in the retrospective group is sum-
marised in Table VIII. The majority of NSCLC patients were
staged as T2. A very small number with T3 disease were
treated surgically. Similarly, most patients were staged as N-0
and N-1. No N-3 patients were treated surgically. Hence
most patients included in the study had stage I and II
disease.
Table VI Percentage of tumours showing 0, 1, 2, 3, 4 and 5 markers
prospective series
No. ofmarkers
0 1 2 3 4 5
Histology No. No. positive
Carcinoid 3 - - - 1 2 -
SQC 27 14 5 4 1 3 -
Ad-SQ 6 3 1 1 - -
Adeno 7 2 3 1 - I
LCU 4 - 3 - I - _
Total % NSCLC 44 43 27 14 4 10 2
The distribution of NE negative and NE positive NSCLC
according to nodal status, disease and tumour stage is shown
in Figures la-c respectively. It can be seen that the following
are NE positive; 26% of NO, 29% of NI and 44% of N2
cases (Figure la); 26% of Stage I, 29% of Stage II, and 43%
of Stage III cases (Figure lb); 26% of TI, 31% of T2 and
43% of T3 cases (Figure lc). A significant association exists
between N-stage and neuroendocrine positivity (2 = 6.1 on
2 d.f., P = 0.05) (Figure la). The highest proportion of NE
positive cases were staged as N2, but a test for trends of
increasing NE positivity with N stage was also statistically
significant (X2 test for linear trend, x2 = 5.2 on 1 d.f.,
P = 0.02). Similarly, a significant association exists between
overall disease stage and neuroendocrine positivity (Q = 6.3
on 2d.f., P = 0.04) (Figure lb). A similar trend is apparent
for T stage (Figure lc); however, these data do not reach
statistical significance (Q = 3.6 on 2 d.f., P = 0.17). Log rank
analysis of each of the individual markers was carried out
but none showed significant difference in survival between
patients positive or negative for the markers. Similarly, there
was no difference in survival between patients with and with-
out NE-NSCLC (X = 0.38 on 1 d.f., P = 0.54).
Multivariate analysis of the individual markers, NE status,
histology, age, sex, T-stage, N-stage and clinical stage was
carried out. The most important prognostic factor was N-
Table VI Prospective cases showing positivity for two or more markers
Case no Histology NSEa BLPa NTa Cg-Aa CK-BBa UJI-3Aa Synapa NE-Ib DCGC
4 Carcinoid + + + NSd NS +++ ++ NS ++ 4 NT
28 Carcinoid + + + NS NS NS ++ NS +++ 3 NT
29 Carcinoid + + + NS ++ +++ + ++ NS 4 + + +
3 SQC +++ ++ ++ NS NS ++ NS 4 +++
6 Adeno ++ ++ ++ NS NS ++ NS 4 + + +
9 Adeno-Sq +++ NS NS ++ ++ ++ +++ 5 +++
11 SQC ++ NS ++ NS ++ NS NS 3 +
12 SQC ++ NS NS NS ++ NS NS 2 -
14 Adeno-Sq ++ ++ NS NS + NS NS 2 + + +
17 SQC + + + NS NS NS ++ NS NS 2 +
18 LCU +++ NS NS NS ++ NS +++ 3 ++
25 SQC +++ + ++ NS NS NS NS 2 NT
30 SQC +++ NS NS +++ NS ++ ++ 4 NT
38 SQC ++ NS NS ++ NS ++ ++ 4 ++
48 SQC +++ NS + NS ++ NS NS 2 ++
aIntensity of immunostaining; where, + weak; + + moderate; + + + intense staining. bNE-I: neuroendocrine index,
defined by the presence of2, 3, 4 or 5 markers. cFrequency of DCGs, where: - none; + rare; + + several; + + + many. dNS = No staining, INT' = No tissue.
Table VIII Patient profile of retrospective series
Sex T stage Nodal stage Disease stage Histology No. Male Female Ti T2 T3 NO Nl N2 I II III
Carcinoida 17 9 8 10 1 - 8 3 - 8 3
SCLC 9 5 4 3 6 - 3 6 - 3 6 -
SQ.CC 191 157 34 65 117 9 116 50 25 110 49 32
Ad-SQ 45 39 6 7 35 3 23 12 10 23 10 12
Adeno 58 43 15 19 38 1 35 12 11 34 12 12
LCU 21 17 4 6 14 1 11 4 6 10 4 7
315 256 59 97 204 14 185 78 52 177 75 63
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Figure la NE status and nodal stage in NSCLC tumours. M,
NO (n= 185); , N1 (n=78); _, N2 (n=52). b, NE status
and disease stage in NSCLC tumours. , Stage I (n
=177);
M, Stage II (n= 75); , Stage III (n =63). c, NE status and
T stage of NSCLC tumours. M, TI (n=97); M, T2
(n=204); , T3 (n= 14).
stage (X2 = 36.2 on 1 d.f., P<0.0001), followed by T-stage
(x2= 11.4 on 1 d.f., P = 0.0007) but no other factor added to
these two (at a significance level of less than 0.05).
Discussion
The observed specificity for normal NE tissues shown by the
markers selected to identify NE-NSCLC tumours suggests
that the presence of one or more NE markers in NSCLC
tumours reflects varying degrees of NE differentiation in
these tumours.
In the present study approximately 50% of NSCLC
tumours stained positively for NSE. Similar findings have
been reported by others (Bergh et al., 1985; Said et al., 1985;
Rode et al., 1985; Dhillon et al., 1985; Linnoila et al., 1988b;
Graziano et al., 1989). The detection of CK-BB immuno-
reactivity in 67% of SCLC and 14% of squamous cell
tumours compares well with previous radioimmunoassay
data (Ruberry et al., 1983). While several studies have failed
to detect bombesin like immunoreactivity in NSCLC using
immunohistochemistry (Addis et al., 1987; Hamid et al.,
1987), a recent study by Linnoila et al., 1988b, reported the
immunohistochemical detection of bombesin like immuno-
reactivity in 13% of NSCLC. In the present study, 8% of
NSCLC tumours showed bombesin like immunoreactivity.
The presence of neurotensin in adenocarcinomas has also
been previously described (Dammrich et al., 1988). The addi-
tional detection of neurotensin in squamous cell and large
cell undifferentiated carcinomas in the present study, possibly
reflects the larger numbers examined. NCAM positivity was
observed in frozen tumour material in one of three carcinoid
tumours and in 20% of non-SCLC cases. A study by Gatter
and Dunnill, 1985, also demonstrated the expression of
NCAM by carcinoid tumours, and, these workers described
focal positivity for this molecule in some NSCLC tumours.
Similarly, Moss et al., 1986, have also reported UJ-13A
immuno-reactivity in large cell lung carcinomas. Synapto-
physin was detected in approximately 23% of NSCLC cases.
In view of its restricted use in acetyl alcohol fixed tissues, the
role of synaptophysin in diagnostic pathology is limited.
An important feature of the present study is the correla-
tion between the presence of DCGs and the detection of two
or more biochemical NE markers in the prospective group of
NSCLC. Although DCGs were identified by electron micro-
scopy, few NSCLC showed evidence of immunoreactivity for
chromogranin-A. Similar findings have been reported by
others (Linnoila et al., 1988b; Grazianno et al., 1989). Such
findings may indicate that NSCLC tumours do not have
sufficient DCGs to enable detection by immunocytochemis-
try.
Since cell differentiation is characterised by the coordin-
ated expression of cell specific groups of genes, the detection
of multiple NE markers within a single neoplasm is likely to
delineate NSCLC tumours with a true endocrine profile. In
the present study the expression of two or more markers
identified all but one of the carcinoid tumours and all SCLCs
and, therefore, was taken to define the neuroendocrine
phenotype. Using this criterion, 30% of NSCLC tumours in
both the retrospective and prospective group were found to
be neuroendocrine. These results compare well with those
reported previously (Linnoila et al., 1988b; Graziano et al.,
1989; Berendsen et al., 1989). Importantly, tumours positive
for two or more markers in our consecutive surgical series
were associated with nodal involvement, particularly N2
disease. Furthermore, such tumours were associated with an
increased likelihood of stage II disease. These findings indi-
cate that NE-NSCLC tumours appear to be more frequently
highly metastatic than non-NE tumours and supports the
contention, based on chemosensitivity studies, that the clini-
cal behaviour of these tumours is similar to that of SCLC.
The findings of this study also show that NE differentiation
in NSCLC is of no prognostic significance with respect to
survival. The ongoing prospective study initiated in parallel
with this retrospective investigation will determine further
whether the presence of NE markers identifies disease with
an inherently more aggressive natural history than that of
non-NE-NSCLC.
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